Form 4: DiaMedica Therapeutics Director Richard Kuntz Reports New Stock Option Grant and Share Holdings

DiaMedica Therapeutics Director Richard Kuntz has reported the grant of 32,162 stock options with an exercise price of $4.11 and updated his beneficial ownership of common shares to 24,210, including restricted stock units.

Summary

• Richard Kuntz, a Director of DiaMedica Therapeutics Inc. (DMAC), filed a Form 4 disclosing changes in his beneficial ownership.
• On June 1, 2025, Mr. Kuntz was granted 32,162 stock options with an exercise price of $4.11 per share.
• These stock options are set to vest in four nearly equal quarterly installments over one year and will expire on May 31, 2035.
• Following this transaction, Mr. Kuntz beneficially owns 24,210 common shares of DiaMedica Therapeutics, which includes 7,443 shares issuable upon the vesting of a restricted stock unit (RSU) award granted under the company's 2019 Omnibus Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing disclosing an insider's equity grant and beneficial ownership, which is neutral in sentiment as it does not contain performance or strategic updates.

Positives

• The grant of 32,162 stock options and the inclusion of 7,443 restricted stock units in Director Richard Kuntz's beneficial ownership align his financial interests with the long-term performance and shareholder value of DiaMedica Therapeutics Inc.
• The vesting schedule for the stock options, over one year, provides a sustained incentive for the director's continued engagement and contribution to the company's success.

Future Outlook

The granted stock options will vest in four nearly equal quarterly installments over one year, indicating future equity accumulation for the director and continued alignment with company performance.

Industry Context

This filing is a standard disclosure of an insider equity transaction, common across all industries as a means of executive and director compensation and alignment. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Related Party Transactions

• Grant of 32,162 stock options and 7,443 restricted stock units to Richard Kuntz, a Director of DiaMedica Therapeutics Inc., as part of his compensation under the company's Amended and Restated 2019 Omnibus Incentive Plan.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns management's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can attract and retain talent.

Next Steps

• Vesting of 32,162 stock options in four nearly equal quarterly installments over one year.
• Vesting of 7,443 restricted stock units.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Richard Kuntz, Form 4, SEC filing, insider transaction, stock options, restricted stock units, beneficial ownership, director compensation, equity grant